Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 26, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA® brand has achieved the position of the #1 Resveratrol Polyphenol Nutraceutical Brand in the United States*.VINIA's leadership position is driven by its clinically demonstrated ability to increase arterial dilation, improving bl ...

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on ...

Core Viewpoint - BioHarvest Sciences Inc. announces the resignation of Mr. David Tsur from its Board of Directors after over four years, and the appointment of Prof. Hezi Levy to the Board, effective immediately [1][2]. Group 1: Board Changes - Mr. David Tsur has been a member of BioHarvest's Board since 2021, contributing significantly to the company's strategic development during a period of operational expansion and product commercialization [2]. - Chairman Zaki Rakib expressed gratitude for Mr. Tsur's leadership and contributions, highlighting his role in supporting the company's growth and strategic evolution [3]. - Prof. Hezi Levy brings decades of leadership experience in Israel's healthcare system, having previously served as Director General of the Israeli Ministry of Health and played a key role during the COVID-19 pandemic [3][4]. Group 2: Prof. Hezi Levy's Background - Prof. Levy has extensive experience, including serving as Head of the Medical Corps of the Israel Defense Forces (IDF) and General Manager of Barzilai Medical Center, overseeing major healthcare operations [4]. - His medical expertise and executive leadership are expected to strengthen BioHarvest's governance as the company scales its direct-to-consumer products and advances its biotechnology CDMO platform [5]. Group 3: Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing patented technology to grow plant-based compounds without the need for the underlying plants [5]. - The company focuses on developing science-based therapeutic solutions in two main areas: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5].

Core Insights - BioHarvest Sciences Inc. has been invited to the 38th Annual Roth Conference, providing a platform to showcase its business to sophisticated investors [1][2] - The company is at a significant inflection point following a successful Q4 2025 financing round, which has fully funded its near-term capital expenditures [2] - BioHarvest has over 85,000 direct customers and is focused on accelerating growth in its Contract Development and Manufacturing Organization (CDMO) and Consumer Product businesses [2] Company Overview - BioHarvest Sciences Inc. specializes in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need for growing the actual plants [3] - The company operates in two main business verticals: as a CDMO for clients seeking novel plant-based compounds and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements [3]

Core Insights - BioHarvest Sciences achieved a significant milestone in 2025, marking its first full year as a NASDAQ-listed company with an annualized revenue run rate exceeding US$36 million and gross margins above 60% [1] - The company is focused on expanding its D2C Products and CDMO Services business units, aiming for continued growth and achieving adjusted EBITDA breakeven in the near term [1] D2C Products Business - The D2C Products business, particularly the VINIA® brand, has seen aggressive growth and product diversification, leveraging the 'VINIA Inside' strategy to enhance brand awareness and market penetration [2] - The VINIA Blood Flow Hydration Solution has received positive consumer feedback and is positioned to capture a share of the US$13 billion Electrolyte Hydration market [3] - Active users of VINIA products have exceeded 85,000, with over 90% of purchases being subscription-based, indicating a strong and predictable revenue stream [4] CDMO Services Division - The CDMO Services division reached a critical inflection point in 2025, securing partnerships across various industries and validating the commercial relevance of its Botanical Synthesis platform [5] - The division is working on two major new plant-based compounds, including a fragrance compound and a saffron-derived compound, with significant market potential [6] - The expectation is that CDMO revenues will surpass those of the Products division as the business continues to scale [6] Financial Strength and Growth - The company improved its balance sheet in 2025, raising approximately US$30.8 million through various financing methods, positioning itself for further growth and efficiency [7] - Increased analyst coverage and trading volume following the NASDAQ listing are seen as positive indicators for achieving a fair market valuation [8] - BioHarvest is fully funded for operational objectives and strategic capital investments, including the development of a new corporate campus and expanded manufacturing facilities [9] Future Priorities - The company's priorities include accelerating revenue growth, expanding margins, and reaching adjusted EBITDA breakeven while executing against a growing CDMO pipeline and expanding the VINIA product ecosystem [11]

Financial Data and Key Metrics Changes - Total revenues increased 39% year-over-year to $9.1 million in Q3 2025, compared to $6.5 million in Q3 2024 [3][13] - Gross profit increased 50% to $5.6 million, representing 61% of total revenue, up from 57% in the same year-ago quarter [13][14] - Adjusted EBITDA loss narrowed to $0.4 million in Q3 2025 from a loss of $1.7 million in Q3 2024 [14] Business Line Data and Key Metrics Changes - Product revenue grew 30% to $8.4 million, while CDMO revenue surged 722% to $0.7 million [13][14] - Core capsules accounted for 88% of product revenues, with new products contributing approximately 30% of growth [4][5] Market Data and Key Metrics Changes - The US VINIA active user base exceeded 75,000 customers, contributing to revenue growth [3] - The launch of VINIA BloodFlow Hydration targets the $17 billion US electrolyte hydration market [9] Company Strategy and Development Direction - The company operates two business verticals: direct-to-consumer products and CDMO services, aiming to drive revenue from both branded products and B2B partnerships [4] - The recent capital raise of $19.9 million will fund the next growth phase, including tripling manufacturing capacity and expanding CDMO services [11][12] - The company aims to achieve adjusted EBITDA break-even by early 2026, with a focus on revenue growth and margin improvement [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA soon, emphasizing the importance of scaling operations and maintaining cost discipline [15][17] - The company is focused on executing the rollout of new products and expanding its Health Pros Affiliate Program to enhance customer acquisition [16][17] Other Important Information - The company secured a new CDMO partnership with SaffronTech to develop saffron-derived compounds, retaining a 25% ownership of the resulting product [5][6] - Gross profit margins improved due to increased manufacturing scale and improved yields [14] Q&A Session Summary Question: Expectations for the ramp-up of the new hydration product - Management indicated a staged launch with initial positive responses and expects a quarter-on-quarter ramp-up in sales, particularly after the broader launch on December 3 [19][22] Question: Update on CDMO opportunities and SaffronTech agreement - Management detailed the collaboration with SaffronTech, emphasizing a fast-tracked development process and the potential for a quick market entry [24][26] Question: Progress on existing CDMO contracts - Management provided updates on ongoing CDMO agreements, highlighting progress in the cosmetic fragrance space and the Tate & Lyle agreement [32][33] Question: Long-term outlook for CDMO business - Management projected that by 2027-2028, approximately 75% of revenue could come from the CDMO business, with margins significantly higher than the product business [47][49] Question: Early success with the HealthPros program - Management reported strong early engagement and conversion rates from HealthPros, with plans to onboard 300 professionals by year-end [41][43]

Core Insights - BioHarvest Sciences Inc. will attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025, in New York, NY [2] - CEO Ilan Sobel will conduct one-on-one meetings with institutional investors during the event [3] - The company is experiencing strong momentum in both its consumer and CDMO divisions, with robust performance in its core VINIA® capsule business and new product lines [4] Company Performance - BioHarvest's VINIA® Daily Chews 2X Formula and VINIA® Blood Flow Hydration Solution are expanding the company's market reach [4] - The CDMO platform has achieved significant milestones, including advancements in plant-based exosome production and a new contract for developing a saffron compound [4] - The company successfully closed a $19.9 million equity offering, which is expected to support its goal of achieving adjusted EBITDA breakeven in the near term [4] Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to grow plant-based compounds without the need for the actual plants [5] - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5]

Core Viewpoint - BioHarvest Sciences Inc. has successfully closed a public offering of common stock, raising $19.9 million to support its growth initiatives and operational needs [2][4]. Group 1: Offering Details - The public offering consisted of 2,846,854 shares at a price of $7.00 per share, including 361,854 shares from the underwriters' option to purchase additional shares [2][3]. - The gross proceeds from the offering amounted to $19.9 million before deducting underwriting discounts and other expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for immediate funding of manufacturing expansion, research and development, marketing, debt reduction or refinancing, capital expenditures, and general corporate purposes, including working capital [3][4]. Group 3: Company Background - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need to cultivate the actual plants [5]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5].

Core Points - BioHarvest Sciences Inc. has announced a public offering of 2,485,000 shares of common stock priced at $7.00 per share, aiming for gross proceeds of approximately $17.4 million [1][2] - The company has granted underwriters a 30-day option to purchase an additional 372,750 shares at the public offering price [1] - The offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on September 8, 2025 [3] Use of Proceeds - The net proceeds from the offering are expected to be utilized for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes, including funding working capital [2] Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to grow plant-based compounds without the need for the underlying plants [5] - The company operates in two major business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5]

Core Viewpoint - BioHarvest Sciences Inc. plans to conduct an underwritten public offering of its common stock, with a potential additional 15% of shares available for purchase by the underwriter [1][2]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the final terms [1]. - Craig-Hallum is the sole managing underwriter for the offering [2]. - A preliminary prospectus supplement will be filed with the SEC, detailing the terms of the proposed offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for various purposes, including research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes [2]. Group 3: Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need to grow the plants [5]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5].